TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This multicenter prospective nonrandomized study is to evaluate the efficacy of TACE combined
with sorafenib compared with TACE monotherapy in term of overall survival in
intermediate-stage HCC.
Phase:
N/A
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University